PD-Loma: a cancer entity with a shared sensitivity to the PD-1/PD-L1 pathway blockade

被引：96

作者：

Hirsch, Laure ^{[1
]}

Zitvogel, Laurence ^{[2
]}

Eggermont, Alexander ^{[3
]}

Marabelle, Aurelien ^{[1
,2
]}

机构：

[1] Univ Paris Saclay, Dept Innovat Therapeut & Essais Precoces, Gustave Roussy, F-94805 Villejuif, France

[2] Univ Paris Saclay, INSERM, U1015, Gustave Roussy, F-94805 Villejuif, France

[3] Univ Paris Saclay, Gustave Roussy, F-94805 Villejuif, France

来源：

BRITISH JOURNAL OF CANCER | 2019年 / 120卷 / 01期

关键词：

OPEN-LABEL; NIVOLUMAB; PEMBROLIZUMAB; MULTICENTER; SAFETY; DOCETAXEL;

D O I：

10.1038/s41416-018-0294-4

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Clinical trials have now identified over 30 cancer histotypes with sensitivity to anti-PD-(L)1 therapies. It is the first time in oncology that a class of drugs has demonstrated such a wide spectrum of activity in monotherapy. This subgroup of cancers ('PD-Lomas') is driving the clinical research strategies for the next generation of combination immunotherapy.

引用

页码：3 / 5

页数：3

共 50 条

[1] PD-1/PD-L1 Axis in Lung Cancer [J].

Santini, Fernando C. ;

Hellmann, Matthew D. .

CANCER JOURNAL, 2018, 24 (01) :15-19

[2] PD-L1 methylation restricts PD-L1/PD-1 interactions to control cancer immune surveillance [J].

Huang, Changsheng ;

Ren, Shengxiang ;

Chen, Yaqi ;

Liu, Anyi ;

Wu, Qi ;

Jiang, Tao ;

Lv, Panjing ;

Song, Da ;

Hu, Fuqing ;

Lan, Jingqing ;

Sun, Li ;

Zheng, Xue ;

Luo, Xuelai ;

Chu, Qian ;

Jia, Keyi ;

Li, Yan ;

Wang, Jun ;

Zou, Caicun ;

Hu, Junbo ;

Wang, Guihua .

SCIENCE ADVANCES, 2023, 9 (21)

[3] PD-L1 copy number gains: a predictive biomarker for PD-1/PD-L1 blockade therapy? [J].

Inoue, Yusuke ;

Osman, Murat ;

Suda, Takafumi ;

Sugimura, Haruhiko .

TRANSLATIONAL CANCER RESEARCH, 2016, 5 :S199-S202

[4] PD-1/PD-L1 pathway blockade works as an effective and practical therapy for cancer immunotherapy [J].

Jia, Long ;

Zhang, Qi ;

Zhang, Rongxin .

CANCER BIOLOGY & MEDICINE, 2018, 15 (02) :116-123

[5] PD-1/PD-L1 blockade in renal cell cancer [J].

Beckermann, Kathryn E. ;

Johnson, Douglas B. ;

Sosman, Jeffrey A. .

EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2017, 13 (01) :77-84

[6] Efficacy of PD-1 or PD-L1 inhibitors and PD-L1 expression status in cancer: meta-analysis [J].

Shen, Xian ;

Zhao, Bin .

BMJ-BRITISH MEDICAL JOURNAL, 2018, 362

[7] PD-1/PD-L1 pathway inhibitors in advanced prostate cancer [J].

Velho, Pedro Isaacsson ;

Antonarakis, Emmanuel S. .

EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2018, 11 (05) :475-486

[8] Cancer immunotherapy and the PD-1/PD-L1 checkpoint pathway [J].

Barclay, Jonathan ;

Creswell, Joanne ;

Leon, Juan .

ARCHIVOS ESPANOLES DE UROLOGIA, 2018, 71 (04) :393-399

[9] Toxicities Associated With PD-1/PD-L1 Blockade [J].

Wang, Daniel Y. ;

Johnson, Douglas B. ;

Davis, Elizabeth J. .

CANCER JOURNAL, 2018, 24 (01) :36-40

[10] Combination of PD-L1 and PVR determines sensitivity to PD-1 blockade [J].

Lee, Bo Ryeong ;

Chae, Sehyun ;

Moon, Jihyun ;

Kim, Myeong Joon ;

Lee, Hankyu ;

Ko, Hyuk Wan ;

Cho, Byoung Chul ;

Shim, Hyo Sup ;

Hwang, Daehee ;

Kim, Hye Ryun ;

Ha, Sang-Jun .

JCI INSIGHT, 2020, 5 (14)

← 1 2 3 4 5 →